GKB Ophthalmics
GKB NSE
GKB Ophthalmics
HealthcareNSE: GKB BSE: 533212 Medical Equipment
Key Fundamentals
MicrocapMedical EquipmentHealthcareMarket Cap
₹32.74 Cr
Volatility
Moderate
P/E Ratio
5.9
EBITDA
₹10.90 Cr
Return on Equity
5.52%
Debt to Equity
0.67
Book Value
₹104.82
52W High
₹74
52W Low
₹60.3
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company has reduced debt.
Weaknesses
6- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 3.74% over past five years.
- Company has a low return on equity of -18.5% over last 3 years.
- Earnings include an other income of Rs.4.58 Cr.
- Company's cost of borrowing seems high
- Promoter holding has decreased over last 3 years: -8.03%
Growth Rate
Revenue Growth
37.17% higher than
3Y
Net Income Growth
-142% lower than
3Y
Cash Flow Change
-11.08% higher than
3Y
ROE
-144% lower than
3Y
ROCE
-237% higher than
3Y
EBITDA Margin (Avg.)
-644% lower than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 9.71 | 7.27 | 6.84 | 7.36 | 8.62 | 8.26 | 7.45 | 8.43 | 8.77 | 6.11 | 4.36 | 6.4 | 6.4 |
| Expenses | 8.72 | 8.12 | 7.85 | 7.77 | 9.05 | 9.3 | 8.27 | 9.61 | 9.62 | 6.74 | 5.41 | 6.85 | 6.65 |
| Operating Profit | 0.99 | -0.85 | -1.01 | -0.41 | -0.43 | -1.04 | -0.82 | -1.18 | -0.85 | -0.63 | -1.05 | -0.45 | -0.25 |
| OPM % | 10.2% | -11.69% | -14.77% | -5.57% | -4.99% | -12.59% | -11.01% | -14% | -9.69% | -10.31% | -24.08% | -7.03% | -3.91% |
| Other Income | 0.09 | 0.07 | 1.72 | 0.2 | 0.09 | 0.06 | 1.81 | 0.01 | 0.07 | 1.37 | 3.24 | -0.5 | 0.47 |
| Interest | 0.37 | 0.38 | 0.36 | 0.48 | 0.41 | 0.4 | 0.48 | 0.6 | 0.68 | 0.57 | 0.6 | 0.32 | 0.3 |
| Depreciation | 0.64 | 0.65 | 0.66 | 0.64 | 0.65 | 0.66 | 0.67 | 0.66 | 0.67 | 0.68 | 0.68 | 0.66 | 0.66 |
| PBT | 0.07 | -1.81 | -0.31 | -1.33 | -1.4 | -2.04 | -0.16 | -2.43 | -2.13 | -0.51 | 0.91 | -1.93 | -0.74 |
| Tax % | 0% | 0% | 0% | 3.01% | 0.71% | 0.49% | 6.25% | 1.65% | 0.94% | 3.92% | -7.69% | -2.07% | -32.43% |
| Net Profit | 0.08 | -1.81 | -0.31 | -1.37 | -1.41 | -2.05 | -0.17 | -2.48 | -2.14 | -0.52 | 0.98 | -1.88 | -0.5 |
| EPS in Rs | 0.16 | -3.59 | -0.62 | -2.72 | -2.8 | -4.07 | -0.34 | -4.92 | -4.25 | -1.03 | 1.94 | -3.73 | -0.99 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 29.85 | 31.17 | 40.65 | 37.43 | 30.47 | 25.56 | 21.34 | 27.05 | 27.73 | 31.18 | 32.75 | 25.64 | 23.27 |
| Expenses | 30.63 | 33.61 | 41.05 | 38.41 | 31.52 | 26.29 | 21.63 | 27.44 | 28.82 | 32.46 | 36.22 | 28.61 | 25.65 |
| Operating Profit | -0.78 | -2.44 | -0.4 | -0.98 | -1.05 | -0.73 | -0.29 | -0.39 | -1.09 | -1.28 | -3.47 | -2.97 | -2.38 |
| OPM % | -2.61% | -7.83% | -0.98% | -2.62% | -3.45% | -2.86% | -1.36% | -1.44% | -3.93% | -4.11% | -10.6% | -11.58% | -10.23% |
| Other Income | 1.72 | 23.08 | 4.11 | 1.05 | 2.62 | 1.38 | 2.33 | 1.91 | 2.09 | 2.08 | 1.97 | 4.18 | 4.58 |
| Interest | 2.49 | 1.61 | 1.26 | 1.23 | 1.39 | 1.35 | 1.34 | 1.34 | 1.5 | 1.59 | 1.89 | 2.17 | 1.79 |
| Depreciation | 1.48 | 1.42 | 1.34 | 1.58 | 3.43 | 3.47 | 2.99 | 2.49 | 2.54 | 2.59 | 2.64 | 2.69 | 2.68 |
| PBT | -3.03 | 17.61 | 1.11 | -2.74 | -3.25 | -4.17 | -2.29 | -2.31 | -3.04 | -3.38 | -6.03 | -3.65 | -2.27 |
| Tax % | -25.41% | 22.43% | 31.53% | -6.2% | -14.77% | 0% | -7.86% | 0% | -5.26% | 1.18% | 1.16% | -2.19% | — |
| Net Profit | -2.26 | 13.66 | 0.76 | -2.58 | -2.78 | -4.17 | -2.11 | -2.31 | -2.88 | -3.42 | -6.11 | -3.57 | -1.92 |
| EPS in Rs | -5.44 | 32.89 | 1.83 | -6.21 | -5.99 | -8.27 | -4.19 | -4.58 | -5.71 | -6.78 | -12.12 | -7.08 | -3.81 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.15 | 4.15 | 4.15 | 4.15 | 4.64 | 5.04 | 5.04 | 5.04 | 5.04 | 5.04 | 5.04 | 5.04 |
| Reserves | 11.14 | 24.8 | 25.44 | 22.78 | 30.03 | 30.21 | 27.73 | 25.36 | 22.48 | 18.95 | 12.63 | 9.28 |
| Borrowings | 8.62 | 7.22 | 7.19 | 9.93 | 10.05 | 10.04 | 11.97 | 11.75 | 11.22 | 11.08 | 18.09 | 9.54 |
| Other Liabilities | 24.79 | 11.36 | 10.22 | 8.57 | 10.45 | 11.4 | 12.13 | 11.74 | 10.41 | 13.32 | 13.72 | 12.75 |
| Total Liabilities | 48.7 | 47.53 | 47 | 45.43 | 55.17 | 56.69 | 56.87 | 53.89 | 49.15 | 48.39 | 49.48 | 36.61 |
| Fixed Assets | 11.72 | 12.49 | 16.43 | 16.98 | 24.29 | 24.83 | 22.28 | 21.27 | 17.28 | 15.89 | 14.44 | 12.49 |
| CWIP | 0.57 | 0.57 | 0.57 | 0.24 | 0 | 0 | 1.23 | 3.29 | 3.82 | 3.78 | 3.78 | 3.78 |
| Investments | 5.53 | 10.45 | 3.77 | 0.66 | 0.32 | 3.21 | 12.22 | 11.9 | 11.9 | 11.9 | 11.9 | 0.19 |
| Other Assets | 30.88 | 24.02 | 26.23 | 27.55 | 30.56 | 28.65 | 21.14 | 17.43 | 16.15 | 16.82 | 19.36 | 20.15 |
| Total Assets | 48.7 | 47.53 | 47 | 45.43 | 55.17 | 56.69 | 56.87 | 53.89 | 49.15 | 48.39 | 49.48 | 36.61 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 5.87 | -11.9 | -4.2 | -3.71 | 5.31 | 6.13 | 2.11 | 2.33 | -1.14 | 1.36 | -5.04 | -1.48 |
| Investing | 0.13 | 14.74 | 5.5 | 2.28 | -8.63 | -5.68 | -11.52 | -0.83 | 2.4 | 0.37 | -0.16 | 12.21 |
| Financing | -6 | -2.81 | -1.29 | 1.41 | 9.21 | 3.31 | 0.61 | -1.5 | -2.03 | -1.74 | 5.12 | -10.72 |
| Net Cash Flow | 0 | 0.02 | 0 | -0.02 | 5.88 | 3.76 | -8.8 | 0 | -0.78 | 0 | -0.07 | 0 |
| Free Cash Flow | 5.24 | -13.83 | -9.08 | -5.27 | -4.35 | 2.44 | -1.2 | -1.34 | 0.25 | 0.16 | -6.43 | -2.06 |
| CFO/OP | -1,028 | 202 | 725 | 366 | -509 | -841 | -728 | -600 | 101 | -107 | 144 | 49 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 177 | 92.63 | 66 | 102 | 129 | 148 | 127 | 80.96 | 64.23 | 80.3 | 83.48 | 73.74 |
| Inventory Days | 351 | 285 | 284 | 264 | 155 | 134 | 257 | 142 | 162 | 102 | 120 | 143 |
| Days Payable | 362 | 120 | 107 | 84.89 | 171 | 223 | 251 | 159 | 139 | 158 | 138 | 139 |
| Cash Conversion Cycle | 165 | 258 | 243 | 281 | 113 | 58.61 | 133 | 63.96 | 86.93 | 24.86 | 65.88 | 77.61 |
| Working Capital Days | -21.15 | 69.79 | 80.72 | 94.59 | -7.67 | -56.12 | -86.38 | -85.68 | -60.02 | -85.22 | -70.1 | -34.17 |
| ROCE % | -3.86% | -6.26% | -0.77% | -4.13% | -8.09% | -6.29% | 0.13% | -2.14% | -3.96% | -4.96% | -11.8% | 0.47% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view GKB Ophthalmics insights
42 extracted metrics + investor summaries across FY11–FY26.
Documents
1
Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Year Ende March 31, 2026.
4 May - Board meets May 27, 2026 to approve audited FY2026 standalone and consolidated results. 4 May - Board meets May 27, 2026 to approve audited FY2026 standalone and consolidated results.
2
Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Year Ende March 31, 2026.
4 May - Board meets May 27, 2026 to approve audited FY2026 standalone and consolidated results. 4 May - Board meets May 27, 2026 to approve audited FY2026 standalone and consolidated results.
3
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Apr - Certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations , 2018, for the quarter ended March 31, 2026. Kindly acknowledge receipt of the … 7 Apr - Certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations , 2018, for the quarter ended March 31, 2026. Kindly acknowledge receipt of the …
4
Non Applicability Of Circular No. SEBI/HO/DDHS/CIR/P/2018/144, Dated November 26, 2018
7 Apr - Company confirms SEBI large corporate circular is not applicable. 7 Apr - Company confirms SEBI large corporate circular is not applicable.
5
Disclosure Under Regulation 31 (4) Of SEBI (Substantial Acquisition Of Shares And Takeover ) Regulation , 2011 For The Financial Year Ended March 31, 2026.
2 Apr - Promoters disclosed no share encumbrance during FY ended March 31, 2026. 2 Apr - Promoters disclosed no share encumbrance during FY ended March 31, 2026.
Frequently Asked Questions about GKB Ophthalmics
What does GKB Ophthalmics Ltd do?
Incorporated in 1981, GKB Ophthalmics Ltd is engaged in the manufacture and sale of ophthalmic lenses made up of Glass and
Plastic.[1]
Where is GKB Ophthalmics Ltd (533212) listed?
GKB Ophthalmics Ltd trades as GKB on the NSE and under code 533212 on the BSE.
Which sector does GKB Ophthalmics Ltd belong to?
GKB Ophthalmics Ltd is classified under the Healthcare sector, in the Medical Equipment industry.
What is the market capitalisation of GKB Ophthalmics Ltd?
GKB Ophthalmics Ltd has a market capitalisation of ₹32.74 Cr, which places it in the Small Cap band.
What is the PE ratio of GKB Ophthalmics Ltd?
GKB Ophthalmics Ltd trades at a PE ratio of 5.90, against a book value of ₹104.82 per share.
What is the 52-week high and low of GKB Ophthalmics Ltd?
Over the last 52 weeks GKB Ophthalmics Ltd has traded between ₹60.3 and ₹74.
What is the Return on Equity (ROE) of GKB Ophthalmics Ltd?
GKB Ophthalmics Ltd reported a return on equity of 5.52%. Its debt-to-equity ratio is 0.67.
Company Information
Incorporated in 1981, GKB Ophthalmics Ltd is engaged in the manufacture and sale of ophthalmic lenses made up of Glass and Plastic.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/533212.md for GKB Ophthalmics Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.